The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to a five-year follow-up of the global ARCHES study led by […]
For patients with amyotrophic lateral sclerosis (ALS), rapid eye movement (REM) inhibition via receipt of antidepressant medication is associated with a trend toward survival benefit, according to a study presented at the American Thoracic Society […]
A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been deemed feasible and tolerable for neuroendocrine cancer patients. The combined therapy works by preventing cancer cells from repairing themselves […]
A new study from researchers at Aarhus University and Aarhus University Hospital found no increased risk of neurodevelopmental disorders in children whose fathers were treated with valproate during spermatogenesis. The results have just been published […]
People who have been taking antidepressants for more than two years are substantially more likely to experience withdrawal symptoms compared to short-term users when they come off the medication, finds a new study led by […]
The U.S. Food and Drug Administration has approved the humanized monoclonal antibody Zynyz (retifanlimab-dlwr) as the first first-line treatment for advanced anal cancer.This article was originally published on MedicalXpress.com
A new study finds that CivicaScript, a not-for-profit drug manufacturer in the US, can reliably supply essential generic medicines at a price that saves patients over 60%, and public and private insurers over 90%, demonstrating […]
A Ludwig Cancer Research study has uncovered a surprising link between diet, intestinal microbes and the efficacy of cancer therapy.This article was originally published on MedicalXpress.com
A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis of 3 […]
Researchers at Sutter’s California Pacific Medical Center (CPMC) in San Francisco, Calif. have discovered early signs of clinical benefit while testing niraparib, a PARP inhibitor, in patients with advanced melanoma whose tumors had specific genetic […]
© 2025 SimplyWell.ca